Spesolimab, an IL-36 receptor antagonist approved for generalized pustular psoriasis, has shown promise in the treatment of PG, as evidenced by several case reports and our patient’s response (16, 17). This evidence concerns the gene IL1RL2 and generalized pustular psoriasis.